• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用西罗莫司为基础的疗法停用环孢素后肾移植中影响肾小球滤过率的因素:五年结果的多变量分析

Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.

作者信息

Legendre Christophe, Brault Yves, Morales José M, Oberbauer Rainer, Altieri Paolo, Riad Hany, Mahony John, Messina Maria, Pussell Bruce, Martínez Javier G, Lelong Magali, Burke James T, Neylan John F

机构信息

Hôpital Necker, Paris, France.

出版信息

Clin Transplant. 2007 May-Jun;21(3):330-6. doi: 10.1111/j.1399-0012.2007.00645.x.

DOI:10.1111/j.1399-0012.2007.00645.x
PMID:17488381
Abstract

Changes in calculated glomerular filtration rate (GFR) from baseline to five yr were analyzed in relation to risk factors among renal transplant recipients. At three months after transplantation (baseline), 430 eligible patients receiving sirolimus (SRL), cyclosporine (CsA), and steroids (ST) were randomly assigned (1:1) to continue SRL-CsA-ST or have CsA withdrawn and SRL trough levels increased (SRL-ST group). For each risk factor, changes from baseline were compared within each treatment using a t-test and between treatments using ANCOVA. Univariate then multivariate robust linear regression analyses were also performed. In the SRL-ST group, changes from baseline were not significantly different for any risk factor. With the exception of cold ischemia time >24 h, GFR values declined significantly for all risk factors in SRL-CsA-ST patients. For all risk factors, except second transplant or cold ischemia time >24 h, renal function was significantly different between groups. By order of significance in the multivariate analysis, treatment (p < 0.001), donor age (p < 0.001), proteinuria (p < 0.001), and biopsy-confirmed rejection (p = 0.010) were significant predictors of GFR change from baseline. In conclusion, patients with risk factors for reduced renal function benefit from SRL maintenance therapy without CsA vs. those remaining on CsA.

摘要

分析了肾移植受者从基线到五年的计算肾小球滤过率(GFR)变化与风险因素的关系。在移植后三个月(基线),430名符合条件的接受西罗莫司(SRL)、环孢素(CsA)和类固醇(ST)治疗的患者被随机分配(1:1)继续接受SRL-CsA-ST治疗或停用CsA并提高SRL谷浓度(SRL-ST组)。对于每个风险因素,使用t检验在每种治疗方法内比较基线变化,并使用协方差分析比较不同治疗方法之间的变化。还进行了单变量和多变量稳健线性回归分析。在SRL-ST组中,任何风险因素的基线变化均无显著差异。除冷缺血时间>24小时外,SRL-CsA-ST患者所有风险因素的GFR值均显著下降。对于所有风险因素,除二次移植或冷缺血时间>24小时外,两组之间的肾功能存在显著差异。按多变量分析中的显著性顺序,治疗(p<0.001)、供体年龄(p<0.001)、蛋白尿(p<0.001)和活检证实的排斥反应(p = 0.010)是GFR从基线变化的显著预测因素。总之,与继续使用CsA的患者相比,存在肾功能降低风险因素的患者从无CsA的SRL维持治疗中获益。

相似文献

1
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.使用西罗莫司为基础的疗法停用环孢素后肾移植中影响肾小球滤过率的因素:五年结果的多变量分析
Clin Transplant. 2007 May-Jun;21(3):330-6. doi: 10.1111/j.1399-0012.2007.00645.x.
2
Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.与持续使用环孢素的西罗莫司相比,停用环孢素后使用西罗莫司具有相似的血脂谱,但长期预后得到改善。
Transplant Proc. 2009 Jul-Aug;41(6):2339-44. doi: 10.1016/j.transproceed.2009.05.009.
3
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.西罗莫司联合他克莫司与西罗莫司联合环孢素在高危肾移植受者中的比较:一项开放标签随机试验的结果
Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.
4
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.在基于西罗莫司的方案中早期停用环孢素可使肾移植受者在移植后48个月时获得更好的移植肾存活和肾功能。
Transpl Int. 2005 Jan;18(1):22-8. doi: 10.1111/j.1432-2277.2004.00052.x.
5
Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.基于西罗莫司的治疗联合或不联合环孢素:肾移植患者的长期随访
Transplant Proc. 2005 Mar;37(2):693-6. doi: 10.1016/j.transproceed.2005.01.045.
6
Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.肾移植受者早期停用环孢素后使用西罗莫司实现肾功能长期改善:雷帕鸣维持治疗方案研究的2年结果
Transplantation. 2003 Jul 27;76(2):364-70. doi: 10.1097/01.TP.0000074360.62032.39.
7
Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.与未使用或联合使用西罗莫司的全剂量环孢素治疗相比,西罗莫司基础治疗使环孢素暴露量降低80%,实际10年肾移植结局更佳。
Transplant Proc. 2011 Dec;43(10):3657-68. doi: 10.1016/j.transproceed.2011.10.052.
8
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.肾移植受者从钙调神经磷酸酶抑制剂转换为西罗莫司维持治疗:CONVERT试验的24个月疗效和安全性结果
Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.
9
Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.停用环孢素后西罗莫司治疗的肾移植患者的三年健康相关生活质量结局
Transpl Int. 2007 Oct;20(10):875-83. doi: 10.1111/j.1432-2277.2007.00547.x.
10
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
Transpl Int. 2007 Sep;20(9):754-60. doi: 10.1111/j.1432-2277.2007.00506.x. Epub 2007 Jun 12.

引用本文的文献

1
Trials evaluating drug discontinuation: a scoping review sub-analysis focusing on outcomes and research questions.评估药物停用的试验:一项聚焦于结局和研究问题的范围综述子分析
BMC Med Res Methodol. 2025 May 27;25(1):146. doi: 10.1186/s12874-025-02597-z.
2
Recipient efficacy and safety of kidney transplantation from older living donor: consideration for using older kidney as a solution to the shortage of organs.老年活体供肾肾移植受者的疗效与安全性:将老年供肾作为解决器官短缺问题的一种方案的考量
Korean J Transplant. 2021 Dec 31;35(4):238-246. doi: 10.4285/kjt.21.0020.
3
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
在参加 Eurotransplant 高级项目的新肾移植受者中使用依维莫司:一项前瞻性随机多中心研究(SENATOR)的结果。
PLoS One. 2019 Sep 19;14(9):e0222730. doi: 10.1371/journal.pone.0222730. eCollection 2019.
4
Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy.将他克莫司转换为贝拉西普可改善移植肾活检显示存在慢性血管病变的肾移植患者的肾功能。
Clin Kidney J. 2018 Dec 1;12(4):586-591. doi: 10.1093/ckj/sfy115. eCollection 2019 Aug.
5
Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.肾移植受者停用或减量钙调神经磷酸酶抑制剂
Cochrane Database Syst Rev. 2017 Jul 21;7(7):CD006750. doi: 10.1002/14651858.CD006750.pub2.
6
Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.肾移植受者从他克莫司晚期转换为基于贝拉西普的免疫抑制方案可改善肾功能、酸碱紊乱和矿物质-骨代谢。
J Nephrol. 2017 Aug;30(4):607-615. doi: 10.1007/s40620-017-0411-0. Epub 2017 May 24.
7
Reviewing 15 years of experience with sirolimus.回顾西罗莫司15年的使用经验。
Transplant Res. 2015 Dec 22;4(Suppl 1):6. doi: 10.1186/s13737-015-0028-6. eCollection 2015.
8
Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?使用扩大标准供体进行肾移植:最佳免疫抑制方案是什么?
World J Transplant. 2016 Mar 24;6(1):103-14. doi: 10.5500/wjt.v6.i1.103.
9
Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?个体化与精准调整:2015年肾移植中个性化免疫抑制治疗的现状如何?
World J Transplant. 2015 Sep 24;5(3):73-80. doi: 10.5500/wjt.v5.i3.73.
10
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.供体年龄和肾脏P-糖蛋白表达与同种异体肾移植的慢性组织学损伤相关。
J Am Soc Nephrol. 2009 Nov;20(11):2468-80. doi: 10.1681/ASN.2009020192. Epub 2009 Sep 17.